Factory Supply Material Acarbose Powder Diabetic Acarbose

• Customization: Available
• CAS No.: 56180-94-0
• Formula: C25h43no18
• Model NO.: QS-Acarbose
• EINECS: 260-030-7
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: >12 Months
• Nutrient Composition: Acarbose
• Resource: Acarbose
• The content of active substances: >99%
• Product Name: Acarbose
• Name: Acarbose Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Density: 1.74
• Mf: C25h43no18
• MW: 645.6
• Melting Point: 165-170 Oc
• Boiling Point: 971.6 Oc at 760 Mmhg
• Refractive Index: 1.689
• Transport Package: Negotiable
• Specification: negotiable
• Trademark: QS
• Origin: Xian
• Production Capacity: 1000 Kg/Month

Product Description

Factory Supply Material Acarbose Powder Diabetic Acarbose 

Product Description

Product Details

Product name	Acarbose
Cas number	56180-94-0
Appearance	White Powder
MF	C25H43NO18
MW	645.6

Acarbose, an oral hypoglycemic drug, is a new oral hypoglycemic drug. It competitively inhibits glucosidase in the intestine, reduces the decomposition of polysaccharide and sucrose to glucose, reduces and delays absorption, and thus has the effect of reducing post-meal hyperglycemia and plasma concentration.
 

Application&Function

pharmacology
As a new type of oral hypoglycemic drug, it competitively inhibits glucosidase in the intestine, can reduce the decomposition of polysaccharide and sucrose to produce glucose, reduce and delay absorption, and therefore has the effect of reducing post-meal hyperglycemia and plasma concentration. This product is less absorbed by oral administration, T1/2 is about 2.8 hours.
[Pharmacological effect] This product can competitively inhibit glucosidase in the intestine, reduce the decomposition of polysaccharide and sucrose to produce glucose, reduce and delay its absorption, and has the effect of reducing post-meal hyperglycemia and plasma concentration.
pharmacokinetics
In healthy subjects, the product has a systemic availability of only 0.5% to 1.7%. After intravenous administration, the steady-state volume of distribution was 0.32L/kg. When given 200mg of this product labeled with carbon-14, about 35% appeared in urine (only 1.7% in its original form) and about 50% was recovered in feces. This product is extensively metabolized by gastrointestinal amylase, which indicates a high systemic clearance (600L per hour). According to the two-compartment model equation, the elimination half-reduction period of this product is about 2.8h.

Specification

About US